NDA 219666 · Ptc Therap
Sephience
Sepiapterin · Oral
NovelOrphanCDER novel approval, Jul 28, 2025: To treat hyperphenylalaninemia in patients with sepiapterin-responsive phenylketonuria, in conjunction with a phenylalanine-restricted diet
Last checked: Nov 20, 2026Latest source record: Jul 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jul 28, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
2 Phase 3, 2 recruiting
FAERS reports
190
21 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 24, 2026.
SEPHIENCE is indicated for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive phenylketonuria (PKU). SEPHIENCE is to be used in conjunction with a phenylalanine (Phe)-restricted diet. SEPHIENCE is a phenylalanine hydroxylase (PAH) activator indicated for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive phenylketonuria (PKU). SEPHIENCE is to be used in conjunction with a phenylalanine (Phe)- restricted diet. ( 1 )
Mechanism: SEPHIENCE is a precursor of the enzymatic co-factor tetrahydrobiopterin (BH 4 ) which activates PAH.
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- SEPHIENCE · SEPIAPTERIN 1GM/PACKET · POWDER, ORAL · Prescription
- SEPHIENCE · SEPIAPTERIN 250MG/PACKET · POWDER, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sepiapterin" as an intervention, any sponsor and status, largest first.
- A Long-Term Safety Study of PTC923 in Participants With PhenylketonuriaPivotal-lookingCompleted
PTC TherapeuticsIndustry
NCT05166161 · 247 participants · Start Feb 14, 2022 · Primary completion Jul 21, 2026
Drug: PTC923 · For: Phenylketonuria
Sites: Aurora, Colorado; Gainesville, Florida; Indianapolis, Indiana · 46 sites in all
- A Study of Sepiapterin in Participants With Phenylketonuria (PKU)Pivotal-lookingRecruiting
PTC TherapeuticsIndustry
NCT06302348 · 56 participants (planned) · Start Mar 4, 2024 · Primary completion Feb 28, 2031
Drug: Sepiapterin · For: Phenylketonuria
Sites: Indianapolis, Indiana; Nedlands, Australia; North Adelaide, Australia · 14 sites in all
PTC TherapeuticsIndustry
NCT03712124 · 21 participants · Start Feb 27, 2019 · Primary completion Sep 8, 2019
Drug: CNSA-001; Placebo · For: Gastroparesis
Sites: Chula Vista, California; Miami, Florida; Indianapolis, Indiana · 6 sites in all
PTC TherapeuticsIndustry
NCT03519711 · 8 participants · Start Jan 3, 2019 · Primary completion Oct 2, 2020
Drug: PTC923 · For: BH4 Deficiency; Hyperphenylalaninemia
Sites: Minneapolis, Minnesota; Dallas, Texas; Salt Lake City, Utah · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product preparation issue55
- drug ineffective19
- diarrhoea16
- abdominal discomfort10
- amino acid level increased10
- tooth discolouration10
- vomiting10
- abdominal pain upper8
- headache7
- skin discolouration7
- nausea6
- product preparation error6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 4 |
| 2026 | 186 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effects of oral sepiapterin on blood Phe concentration in a broad range of patients with phenylketonuria (APHENITY): results of an international, phase 3, randomised, double-blind, placebo-controlled trial.
Muntau AC, Longo N, Ezgu F, et al. · Lancet 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of sepiapterin versus sapropterin in patients with phenylketonuria: Results from the Phase 3, randomized, crossover, open-label, active-controlled AMPLIPHY trial.
Giżewska M, Inwood A, Tyčová R, et al. · Metabolism 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Effect of long-term sepiapterin treatment on dietary phenylalanine tolerance in patients with phenylketonuria: Interim results from the phase 3 APHENITY Extension Study.
van Spronsen F, Peters H, Margvelashvili L, et al. · Genet Med 2026 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Superoxide production, risk factors, and endothelium-dependent relaxations in human internal mammary arteries.
Huraux C, Makita T, Kurz S, et al. · Circulation 1999 · Clinical Trial
- Follow-up and outcome of patients with primary BH4 deficiencies.
Nardecchia F, Manti F, De Giorgi A, et al. · Front Neurol 2026 · Systematic Review
- Relative Oral Bioavailability and Food Effects of Two Sepiapterin Formulations in Healthy Participants.
Gao L, Kaushik D, Xia Y, et al. · Clin Pharmacol Drug Dev 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Ptc Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.